HeraMED Statistics

Total Valuation

HeraMED has a market cap or net worth of AUD 55.44 million. The enterprise value is 54.07 million.

Market Cap	55.44M
Enterprise Value	54.07M

Important Dates

The next estimated earnings date is Thursday, May 28, 2026.

Earnings Date	May 28, 2026
Ex-Dividend Date	n/a

Share Statistics

HeraMED has 1.15 billion shares outstanding. The number of shares has increased by 101.27% in one year.

Current Share Class	1.15B
Shares Outstanding	1.15B
Shares Change (YoY)	+101.27%
Shares Change (QoQ)	+44.45%
Owned by Insiders (%)	4.64%
Owned by Institutions (%)	6.44%
Float	813.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	128.45
PB Ratio	59.55
P/TBV Ratio	59.55
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-13.09
EV / Sales	125.27
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.49

Current Ratio	4.49
Quick Ratio	4.38
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-913.77

Financial Efficiency

Return on equity (ROE) is -223.20% and return on invested capital (ROIC) is -127.04%.

Return on Equity (ROE)	-223.20%
Return on Assets (ROA)	-80.46%
Return on Invested Capital (ROIC)	-127.04%
Return on Capital Employed (ROCE)	-329.15%
Weighted Average Cost of Capital (WACC)	6.07%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +200.00% in the last 52 weeks. The beta is 0.33, so HeraMED's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	+200.00%
50-Day Moving Average	0.04
200-Day Moving Average	0.03
Relative Strength Index (RSI)	59.50
Average Volume (20 Days)	1,339,119

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HeraMED had revenue of AUD 431,605 and -4.13 million in losses. Loss per share was -0.00.

Revenue	431,605
Gross Profit	50,465
Operating Income	-3.85M
Pretax Income	-4.13M
Net Income	-4.13M
EBITDA	-3.82M
EBIT	-3.85M
Loss Per Share	-0.00

Full Income Statement

Balance Sheet

The company has 1.37 million in cash and n/a in debt, with a net cash position of 1.37 million or 0.00 per share.

Cash & Cash Equivalents	1.37M
Total Debt	n/a
Net Cash	1.37M
Net Cash Per Share	0.00
Equity (Book Value)	931,029
Book Value Per Share	0.00
Working Capital	1.13M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-3.66M
Capital Expenditures	n/a
Depreciation & Amortization	22,297
Net Borrowing	-68,917
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	11.69%
Operating Margin	-891.10%
Pretax Margin	-957.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

HeraMED does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-101.27%
Shareholder Yield	-101.27%
Earnings Yield	-7.45%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HeraMED has an Altman Z-Score of -24.32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-24.32
Piotroski F-Score	3